CPI 1714
Alternative Names: NRT 115Latest Information Update: 14 Jun 2004
At a glance
- Originator Renovis
- Class Antirheumatics
- Mechanism of Action Free radical scavengers; Mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 14 Jun 2004 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
- 16 Dec 2002 Centaur Pharmaceuticals has been acquired by Renovis
- 19 Dec 2000 CPI 1714 is available for licensing (http://www.centpharm.com/)